Form 10-Q · Quarterly report
Bristol Myers Squibb 10-Q, filed Oct 29, 2026
- Filed
- CIK
- 0000014272
- Accession no.
- 0000014272-26-000024
Summary
Bristol Myers Squibb (BMY) reported third-quarter 2026 total revenues of $13.1 billion, up 7% from a year earlier, with GAAP diluted EPS of $1.05 and non-GAAP diluted EPS of $1.35. The company cited 2026 regulatory approvals for Zenbexus, Camzyos, Sotyktu and Opdivo, pipeline advances including positive ALOFT-IPF results for admilparant, and a target of about $2.0 billion in annual cost savings by the end of 2027.
Key points
- Q3 2026 total revenues were $13.07 billion, up 7% year over year, and nine-month revenues were $37.53 billion, up 5%.
- Q3 2026 GAAP diluted EPS was $1.05 versus $1.08 a year earlier; non-GAAP diluted EPS was $1.35 versus $1.63.
- 2026 approvals included Zenbexus (iberdomide) with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma, Camzyos for pediatric oHCM, Sotyktu for psoriatic arthritis, and Opdivo for classical Hodgkin lymphoma.
- BMY expects about $2.0 billion in annual cost savings by the end of 2027 and in May 2026 entered global license agreements with Hengrui for 13 early-stage oncology, hematology and immunology assets.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. MANAGEMENT’S DISCUSSION EXECUTIVE SUMMARY Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry. Our focus as a biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases in areas where we believe that we have an opportunity to make a meaningful difference: oncology, hematology, immunology, cardiovascular, neuroscience and other areas where we can also create long-term value. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.